


Ask a doctor about a prescription for LAPRYSTA 100 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Laprysta 100 mg film-coated tablets EFG
lacosamida
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
What is Laprysta
This medicine contains lacosamida, which belongs to a group of medicines called “antiepileptic medicines”. These medicines are used to treat epilepsy.
What lacosamida is used for
Do not take Laprysta
Do not take this medicine if any of the above applies to you. If you are not sure, consult your doctor or pharmacist before taking this medicine.
Warnings and precautions
Consult your doctor before starting to use this medicine if:
If any of the above applies to you (or you are not sure), consult your doctor or pharmacist before taking this medicine.
If you are taking Laprysta, consult your doctor if you experience a new type of seizure or worsening of existing seizures.
If you are taking Laprysta and experience symptoms of abnormal heartbeat (such as slow, fast, or irregular heartbeat, palpitations, shortness of breath, dizziness, fainting), consult your doctor immediately (see section 4).
Children
Lacosamida is not recommended in children under 2 years of age with epilepsy characterized by the occurrence of partial-onset seizures and is not recommended for children under 4 years of age with primary generalized tonic-clonic seizures. This is because it is not yet known if it is effective and safe for children in this age group.
Other medicines and Laprysta
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect the heart. The reason is that lacosamida may also affect the heart.
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine.
Also, inform your doctor or pharmacist if you are taking any of the following medicines. The reason is that they may also increase or decrease the effect of lacosamida in your body.
If any of the above applies to you (or you are not sure), talk to your doctor or pharmacist before taking lacosamida.
Taking Laprysta with alcohol
As a precaution, do not take this medicine with alcohol.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Lacosamida is not recommended if you are pregnant or breastfeeding, as it is not known what effect this medicine has on pregnancy and the fetus or the newborn baby. Also, it is not known if lacosamida passes into breast milk. Ask your doctor for advice immediately if you are pregnant or planning to become pregnant. They will help you decide whether to take lacosamida or not.
Do not stop treatment without talking to your doctor first, as this may increase the risk of seizures (fits). Worsening of your condition may also harm the fetus.
Driving and using machines
Do not drive, ride a bicycle, or use any tools or machines until you know if this medicine affects you. The reason is that lacosamida may cause dizziness or blurred vision.
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. Other forms of this medicine may be more suitable for children; consult your doctor or pharmacist.
Taking Lacosamida
Normally, you will start by taking a low dose each day and your doctor will gradually increase the dose over several weeks. When you reach the dose that works well for you, which is called the “maintenance dose”, you will take the same amount every day. Lacosamida is used as long-term treatment. You should continue taking lacosamida until your doctor tells you to stop.
How much to take
The following are the usual recommended doses of lacosamida for different age and weight groups. Your doctor may prescribe a different dose if you have kidney or liver problems.
Adolescents and children weighing 50 kg or more and adults
When taking lacosamida alone:
The usual starting dose is 50 mg twice a day.
Your doctor may also prescribe a starting dose of 100 mg of lacosamida twice a day. Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 300 mg twice a day.
When taking lacosamida with other antiepileptic medicines:
The usual starting dose is 50 mg twice a day.
Your doctor may increase the dose you take twice a day by 50 mg each week, until you reach a maintenance dose between 100 mg and 200 mg twice a day.
If you weigh 50 kg or more, your doctor may start lacosamida treatment with a single “loading dose” of 200 mg. Then you would start taking the continuous maintenance dose 12 hours later.
Children and adolescents weighing less than 50 kg
If you take more lacosamida than you should
If you have taken more lacosamida than you should, talk to your doctor immediately. Do not attempt to drive.
You may experience:
If you forget to take lacosamida
If you stop taking lacosamida
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, lacosamida can cause side effects, although not everybody gets them.
Side effects in the nervous system, such as dizziness, may be greater after a single “loading dose”.
Tell your doctor or pharmacist if you get any of the following effects:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Frequency not known: cannot be estimated from the available data
Other side effects in children
Additional side effects seen in children were fever (pyrexia), runny nose (nasopharyngitis), sore throat (pharyngitis), eating less than usual (decreased appetite), behavioral changes, not acting as they normally do (abnormal behavior), and lack of energy (lethargy). Drowsiness (somnolence) is a very common side effect in children and may affect more than 1 in 10 children.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use website: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
Composition of Laprysta
Core of the tablet: microcrystalline cellulose (E460), low-substituted hydroxypropylcellulose, crospovidone (type B), hydroxypropylcellulose (E463), silicified microcrystalline cellulose, magnesium stearate.
Coating: polyvinyl alcohol, macrogol, talc, titanium dioxide (E171), yellow iron oxide (E172).
Appearance of the product and contents of the pack
Laprysta 100 mg are film-coated tablets of dark yellow color, oblong, engraved with 'LAC' on one side, and “100” on the other.
Laprysta 100 mg is available in packs of 14, 56, and 84 film-coated tablets in transparent PVC/PVDC blisters sealed with an aluminum foil.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Neuraxpharm Spain, S.L.U.
Avda Barcelona, 69
08970 Sant Joan Despí
Barcelona – Spain
Manufacturer
Combino Pharm Ltd.
HF60 Hal Far Industriale Estate
BBG3000
Malta
SVUS Pharma a.s.
Smetanovo nábreží 1238/20a
500 02 Hradec Králové
Czech Republic
Galenica Pharmaceutical Industry, S.A.
Asklipiou 4-6,
Kryoneri, Athens,
14568, Greece
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain: Laprysta 100 mg film-coated tablets EFG
Italy: Laprysta 100 mg film-coated tablets
Date of last revision of this leaflet:September 2022
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of LAPRYSTA 100 mg FILM-COATED TABLETS in November, 2025 is around 65.78 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LAPRYSTA 100 mg FILM-COATED TABLETS – subject to medical assessment and local rules.